Physician profile
Thomas Cheriyan
NPI 1659738128
$1,539.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.03 · 2020: $370 · 2021: $742 · 2022: $367.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $385.28 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.23 | 2021-2022 | |
| Medtronic USA, INC. | $171.83 | 2019-2020 | |
| Nalu Medical, INC. | $146.55 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $124.99 | 2020 | |
| Uswm, LLC | $117.95 | 2021 | |
| Spr Therapeutics, INC | $111.11 | 2022 | |
| Nevro Corp. | $103.88 | 2020 | |
| Forte Bio-Pharma LLC | $50.17 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $40.05 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $33.96 | 2021 | |
| Horizon Therapeutics Plc | $29.81 | 2022 | |
| Trevena, INC. | $25.74 | 2021 | |
| Redhill Biopharma INC. | $20.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cheriyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.